WALTHAM, Mass., Sept. 17 /PRNewswire-FirstCall/ -- Interleukin Genetics (Amex: ILI - News) today announced that its President and Chief Scientific Officer, Kenneth Kornman, DDS, PhD, will present at the Immunotoxicology V Conference on September 17-18, 2007 in Alexandria, VA. The conference will focus on innovative methods and applications for risk assessment in pharmaceutical development.
Among a group of presenters that includes industry regulators and some of the industry''s leading researchers from major biotechnology and pharmaceutical companies, Dr. Kornman will be discussing multiple ways in which genetic variations in innate immunity may influence drug responses, and be relevant to drug development. As one example, he will discuss how certain genetic variations influence biological drug responses in the treatment of rheumatoid arthritis.
"Because of the critical role played by innate immunity in so many diseases, the potential for genetic variation to produce unexpected responses may be substantial," Dr. Kornman said. "We now know that genetic variations that regulate inflammatory responses make some individuals more responsive to a disease challenge but also more responsive to treatment. This information has great implications for drug development. We are currently using the genetic factors that control certain inflammatory responses to develop preventive and therapeutic products for genetically-targeted populations with common chronic diseases."
For more information on the conference or Interleukin please visit
About Interleukin
Interleukin Genetics, Inc. (Amex: ILI - News) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals, including Ginkoba®, Ginsana? and Venastat? which are sold at the nation''s largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit
Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006 as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10- Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics: Paul Voegelin (781) 398-0700 Additional Contacts for Media / Investors: Erin Duggan (212) 445-8238, Weber Shandwick Rich Tauberman (201) 964-2408, Financial Relations Board
Source: Interleukin Genetics
|
原标题：【Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference】 内容摘要：WALTHAM, Mass., Sept. 17 /PRNewswire-FirstCall/ -- Interleukin Genetics (Amex: ILI - News) today announced that its President and Chief Scientific Officer, Kenneth Kornman, DDS, PhD, will present at the Immunotoxicology V Conference on September 17 ... 文章网址：https://www.doukela.com/toutiao/66932.html； 免责声明：抖客网转载此文目的在于传递更多信息，不代表本网的观点和立场。文章内容仅供参考，不构成投资建议。如果您发现网站上有侵犯您的知识产权的作品，请与我们取得联系，我们会及时修改或删除。 |
